Illumina Inc(ILMN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 50.21 | EPS (ttm) | 5.37 | Insider Own | 0.34% | Shs Outstand | 151.0M | Perf Week | 2.62% |
| Market Cap | 40.68B | Forward P/E | 44.18 | EPS next Y | 13.91% | Insider Trans | -85.66% | Shs Float | 150.5M | Perf Month | -1.64% |
| Enterprise Value | 42.04B | PEG | 3.4 | EPS next Q | 1.36 | Inst Own | 114.55% | Short Float | 6.29% | Perf Quarter | 42.2% |
| Income | 0.82B | P/S | 9.05 | EPS this Y | 10.62% | Inst Trans | 4.51% | Short Ratio | 3.42 | Perf Half Y | 110.68% |
| Sales | 4.50B | P/B | 14.33 | EPS next 5Y | 12.98% | ROA | 12.95% | Short Interest | 9.47M | Perf YTD | 105.41% |
| Book/sh | 18.79 | P/C | 34.83 | EPS past 3/5Y | - 4.22% | ROE | 32.38% | 52W High | -12.91% ($309.35) | Perf Year | 169.5% |
| Cash/sh | 7.74 | P/FCF | 43.7 | Sales past 3/5Y | -1.82% 6.02% | ROIC | 17.25% | 52W Low | 186.62% ($94.00) | Perf 3Y | 132.05% |
| Dividend Est. | - | EV/EBITDA | 36.06 | EPS Y/Y TTM | -31.78% | Gross Margin | 66.81% | Volatility(W/M) | 6.03% 5.49% | Perf 5Y | -32.24% |
| Dividend TTM | - | EV/Sales | 9.35 | Sales Y/Y TTM | 4.97% | Oper. Margin | 19.87% | ATR (14) | 14.2 | Perf 10Y | 95.51% |
| Dividend Ex-Date | - | Quick Ratio | 1.4 | EPS Q/Q | -9.61% | Profit Margin | 18.35% | RSI (14) | 54.66 | Recom | 2.42 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.8 | Sales Q/Q | 9.84% | SMA20 | -0.88% ($271.81) | Beta | 1.45 | Target Price | $253.32 |
| Payout | - | Debt/Eq | 0.89 | Earnings | 2026/10/29 | SMA50 | 11.42% ($241.81) | Rel Volume | 0.46 | Prev Close | $269.4 |
| Employees | 8600 | LT Debt/Eq | 0.69 | EPS/Sales Surpr. | 6.83% 2.51% | SMA200 | 55.83% ($172.89) | Avg Volume(3M) | 2.77M | Price | $269.42 |
| IPO | 2000/7/28 | Option/Short | Yes/Yes | Trades | 19934 | Volume | 1,262,922 | Change | 0.01% |
🧬 Illumina Inc is a leading global company in the next-generation sequencing (NGS) field. It supplies high-throughput sequencing instruments and dedicated reagents for genetic analysis, driving growth in the biotechnology research and diagnostics markets. With a large installed base at research institutes and medical institutions worldwide, the company has built a stable consumables revenue structure.
Over the past 1 year, on the higher side
13% below its 1-year high.
Traded less than usual. That is 46% of its average volume.
Next earnings report: October 29
3 days to go.
ILMN makes money exceptionally well
Of every $100 in sales, $19.87 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.6% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $5,021. Peers typically go for $3,633. Compared with its own 2-year average, it is 48% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -32.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 114.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #8 of 44 in the industry
Based on market cap of $41B.
FAQ
What kind of company is ILMN?
ILMN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ILMN?
The market cap of ILMN is approximately $40.7B, ranking 377 within its sector.
What is the P/E ratio of ILMN?
ILMN has a P/E ratio of approximately 50.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ILMN?
ILMN has recorded a 52-week high of $309.35 and a low of $94.00.
